Tilray, Inc. Reports Second Quarter 2019 Monetary Results 


  • Total kilogram equivalents sold additional than tripled to five,588 kilograms from 1,514 kilograms in the prior year period.
  • Typical net promoting price tag per gram decreased to $four.61 (C$six.12) compared to $six.38 (C$eight.36) in the prior year period. The typical net promoting price tag excluding excise taxes was $three.92 (C$five.20) per gram for the second quarter of 2019. The lower was due to a lowered mix of larger priced extract goods and a higher mix of adult-use income, which are at reduced costs per gram compared to other channels.
  • Gross margin enhanced sequentially to 27% from 23% in the prior quarter. Gross margin in the second quarter of 2018 was 43%. Gross margin continues to be impacted by enhanced expenses incurred with the ramping up of cultivation facilities in Canada and Portugal and acquiring third celebration provide. Meals solution margins have been also impacted by a $1.four million non-money charge connected to buy accounting for the fair worth of inventory.  Excluding this buy accounting charge, gross margin was 30% for the quarter.
  • Net loss for the quarter was $35.1 million or $.36 per share compared to a loss of $12.eight million or $.17 per share for the prior year period. The adjusted net loss for the quarter was $31.two million or $.32 per share for the second quarter of 2019. The adjustments to the net loss are non-recurring acquisition connected charges and a non-recurring non-money charge connected to buy accounting for the fair worth of inventory. Adjusted EBITDA was a loss of $17.9 million compared to a loss of $four.7 million the prior year period. The enhanced net loss and Adjusted EBITDA declines have been mainly due to the raise in operating expenditures connected to development initiatives, interest expense from our convertible notes, the addition of Manitoba Harvest and Natura enterprises, and the expansion of international operations.

Company Highlights  

  • Signed Letter of Intent (LOI) with Privateer Holdings, Inc. to extend lock-up for up to two years and deliver for orderly release of the 75 million Tilray shares held by Privateer.
  • Considerable capacity expansion:
    • Expanded international export capacity with regular manufacturing license and Superior Manufacturing Practices (GMP) certification for EU Campus that enables Tilray Portugal to manufacture and export GMP-certified dried cannabis as an active substance for medicinal goods.
    • Elevated international export capacity with an more 20 hectares (50 acres) of outside cultivation space in Portugal by means of a Definitive Agreement with Esporão, a single of the biggest and most sophisticated agricultural enterprises in Portugal. This agreement will expand Tilray’s total production and manufacturing footprint to three.four million square feet worldwide.
    • Announced an investment of $32.six million to raise our Canadian production and manufacturing footprint by 203,000 square feet across 3 facilities in Nanaimo, British Columbia, Leamington, Ontario, and London, Ontario.
  • Important international marketplace developments:
    • Imported GMP-certified completed health-related cannabis oil options into Ireland for nationwide distribution below the Health-related Cannabis Access Programme.
    • Manitoba Harvest launched a Broad Spectrum Hemp Extract line that is Usually Recognized as Secure (GRAS) in the United States, marking Tilray’s initially entry into the U.S. CBD marketplace below this brand.
  • Expanding our brand portfolio:
    • Acquired Smith &amp Sinclair, an revolutionary U.K.-primarily based confectionary firm that will introduce CBD-infused customer goods exactly where regulations permit. 
  • Clinical analysis developments:
    • Announced help of two new clinical research: a pilot study led by Murdoch Children’s Analysis Institute (MCRI) in Melbourne, Australia, to evaluate the feasibility and acceptability of a bigger randomized placebo-controlled trial of cannabis extract as a kind of therapy for decreasing Serious Behavioral Challenges (SBP) in pediatric individuals with Intellectual Disabilities (ID) and a study with McGill University Well being Centre’s Division of Infectious Illnesses and Chronic Viral Illness in Quebec, Canada to examine the effectiveness of health-related cannabis on immune activation in Folks Living with HIV.
    • Imported an initial shipment of health-related cannabinoids into the United States, with approval from the U.S. government, to help two clinical trials led by NYU College of Medicine for individuals with Alcohol Use Disorder and Post-Traumatic Pressure Disorder with Alcohol Use Disorder.
  • Expanded international senior leadership group:
    • Appointed Kristina Adamski as Executive Vice President of Corporate Affairs, globally overseeing communications, government affairs and corporate social duty.
    • Strengthened European leadership group with the appointment of Arne Wilkens as Vice President, Company Expansion, Europe José Tempero as Health-related Affairs Director, Europe Maike Gerlach as Vice President, Advertising and marketing, Europe Nadja Frenzel as Vice President, Industrial Improvement, Europe and Natalie Bucceri as Director, International Portfolio Expansion.

Conference Get in touch with

The Business will host a conference contact to go over these benefits right now at five:00 p.m. ET. Investors interested in participating in the reside contact can dial 877-489-6528 from the U.S. and 629-228-0736 internationally. A phone replay will be accessible around two hours immediately after the contact concludes by means of Tuesday, August 27, 2019, by dialing 855-859-2056 from the U.S., or 404-537-3406 from international areas, and getting into confirmation code 1489081.

There will also be a simultaneous, reside webcast accessible on the Investors section of the Company’s site at www.tilray.com. The webcast will be archived for 30 days.

Additional data on Q2 earnings can be discovered on ir.tilray.com. 


Latest posts